Real World Study on the Current Status and Influencing Factors of Antiplatelet Aggregation Drugs Use among People Aged 40 and above in Baotou, Inner Mongolia
YU Wenlong, BAI Ruyu, YU Yanxue, GUO Xia, WU Lie
2023, 18(06):
651-659.
DOI: 10.3969/j.issn.1673-5765.2023.06.006
Asbtract
(
)
PDF (1924KB)
(
)
References |
Related Articles |
Metrics
Objective To clarify the use of antiplatelet aggregating drugs in people aged 40 years and above in Baotou area of Inner Mongolia in the real world, and the factors influencing the rate of taking drugs in different populations.
Methods A multilevel, whole-group, random sampling method with neighborhood and village committees was used to draw permanent residents aged 40 years and above in Baotou area from June 2021 to September 2022. A questionnaire was used to collect general information, past medical history and the use of anti-platelet aggregating drugs from the study population. The subjects were divided into three groups according to the presence or absence of cardio cerebrovascular diseases (CVD) and the presence of CVD risk factors: CVD group (with previous CVD), CVD risk factor group (no history of CVD, with one or more of the following CVD risk factors: hypertension, diabetes mellitus, hyperlipidemia, history of smoking, history of alcohol consumption, obesity), the healthy control group (no history of CVD, no risk factors for CVD). The differences in general information between the 3 groups were compared. The subjects in the CVD group and the CVD risk factor group were divided into the medication group and the non-medication group according to whether they were taking antiplatelet aggregation drugs or not, and the relevant factors affecting medication taking in the two groups were investigated using univariate and multifactorial analyses.
Results ①A total of 2100 validated subjects were included in the study, including 298 cases (14.2%) in the CVD group, 1040 cases (49.5%) in the CVD risk factor group, and 762 cases (36.3%) in the healthy control group.The rates of taking antiplatelet aggregation drugs in the three groups were 51.68% (154 cases), 33.46% (348 cases), and 6.69% (51 cases), respectively, with statistically significant differences between groups (P<0.001). ②Multifactorial analysis showed that higher education (primary school education or less as the baseline, high school OR 2.429, 95%CI 1.277-4.619, P=0.007, undergraduate education or above OR 8.500, 95%CI 1.015-12.165, P=0.048) and combined diabetes mellitus (OR 2.820, 95%CI 1.377-5.777, P=0.005) were more likely to apply anti-platelet aggregation drugs in the CVD group; the rate of anti-platelet aggregation drug application in the CVD risk factor group was affected by personal economic income (baseline<10 000/year, >50 000/year, OR 18.547, 95%CI 8.948-38.444, P<0.001), education (primary school education or less as the baseline, bachelor's degree and above, OR 5.512, 95%CI 1.736-17.495, P=0.004), smoking history (OR 0.712, 95%CI 0.541-0.936, P=0.015), normal BMI (compared to low BMI patients, OR 5.640, 95%CI 1.172-27.144, P=0.031), obesity (OR 8.440, 95%CI 1.684-42.293, P=0.009), having hypertension (OR 246.029, 95%CI 112.44-538.337, P<0.001), having diabetes (OR 117.689, 95%CI 51.041-271.367, P<0.001) were independently influenced by other factors. ③The reasons for taking medication in the CVD and CVD risk factor groups were the highest among physician prescriptions, 83.12% and 79.60%, respectively; the reasons for taking medication in the healthy control group were, in descending order, consciously should take it (47.06%), introduced by friends and relatives (29.41%), advertised media (13.73%), and physician prescription (9.80%).
Conclusions The use of antiplatelet aggregation drugs for primary and secondary prevention of CVD among people aged 40 years and above in Baotou, Inner Mongolia is not satisfactory, and the factors influencing the use of drugs vary among different groups, and there are cases of irregular or even incorrect use of drugs among healthy people.
